@article{176bff94df7b42ff8aec6caeaee5a112,
title = "Inflammation in Experimental Models of α-Synucleinopathies",
abstract = "Neuroinflammation has long been associated with central nervous system pathology in α-synucleinopathy disorders including Parkinson's disease and multiple system atrophy. In the past decade, research-focused efforts in preclinical and experimental models have rallied around this idea, and considerable effort has been made to delineate critical neuroinflammatory processes. In this article, we discuss challenges in preclinical research, notably the use of animal models to recapitulate and dissect disease phenotypes as well as the need for more sensitive, reliable radiotracers to detect on-target efficacy of immunomodulatory treatments in both human Parkinson's disease as well as preclinical models.",
keywords = "Parkinson's disease; multiple system atrophy; neuroinflammation; alpha-synuclein; T cells; microglia; neurotoxins; antigen; radiotracer; positron emission tomography",
author = "Harms, {Ashley S.} and Kordower, {Jeffrey H.} and Alessandro Sette and {Lindestam Arlehamn}, {Cecilia S.} and David Sulzer and Mach, {Robert H.}",
note = "Funding Information: The authors declare no link of interest related to the present article. In the past 12 months, these are the financial disclosures: Ashley S. Harms is supported by the National Institutes of Health, US Department of Defense, and the Michael J Fox Foundation. Jeffrey H. Kordower has received commercial support as a consultant from Cellular Dynamics International, Inc, Michael J. Fox Foundation, Abbvie, Exicure, NSGENE, Guidepoint, Inhibikhase, Axovant, and Seelos. Alessandro Sette and Cecilia S. Lindestam Arlehamn have no competing financial interests. David Sulzer received honoraoria from multiple universities and sceintific meetings for giving scientific lectures, patents through Columbia University, from publishing for journal editing, and salary from Columbia, New York State, National Institutes of Health, and private funding organizations including Michael J Fox, JPN, and the Simons Foundations. Robert H. Mach is a cofounder of Accuronix Therapeutics, Trevarx, and Velum Biosciences. He has received support from Five Eleven Pharma. Nature Publisher Copyright: {\textcopyright} 2020 International Parkinson and Movement Disorder Society",
year = "2021",
month = jan,
doi = "10.1002/mds.28264",
language = "English (US)",
volume = "36",
pages = "37--49",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "1",
}